« Return to News | Drug Sponsors

Astellas exercises buy-out option for Perseid

Friday, March 18, 2011 01:35 PM

Astellas Pharma has exercised a buy-out option to acquire all of Maxygen’s ownership interest in Perseid Therapeutics, the joint venture between Maxygen and Astellas, according to Fierce Biotech.  Maxygen and Perseid are based in Redwood City, Calif.

They formed the collaboration in 2009 to focus on the discovery and R&D of multiple protein pharmaceutical programs, including Maxygen's MAXY-4 program. The transaction is expected to close within three months.  

Astellas will pay Maxygen $76 million, and Perseid will become its wholly-owned subsidiary. In addition, Astellas will become sole owner of the MAXY-4 program. The MAXY-4 proteins are intended to reduce T-cell activation and lessen the immune response in rheumatoid arthritis and transplant rejection.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.